Haesun Choi

Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials

Alexander D. Sherry, Van To, Criselle D’souza, Simin Kiany et autres

us, au (code pays fourni par la source)

Metastasis-directed therapy with or without pembrolizumab for oligometastatic clear cell renal cell carcinoma: Pooled analysis of two prospective single-arm phase II trials.

Alexander D. Sherry, Van To, Criselle D'souza, Simin Kiany et autres

498 Background: Radiotherapy-based metastasis-directed therapy (MDT) has emerged as a viable treatment paradigm for oligometastatic clear cell renal cell carcinoma (ccRCC). However, the optimal integration of MDT with frontline immune checkpoint inhibition (ICI) is unclear, especially in light of the M1 NED …

us, au (code pays fourni par la source)

7Phase 2 trial of metastasis directed radiotherapy without systemic therapy (MRWS) for oligometastatic clear cell renal cell carcinoma (ccRCC) and investigation of circulating tumor DNA (ctDNA)

Chad Tang, A. Dean Sherry, Aaron Seo, Kieko Hara et autres

Abstract Background Current treatment for frontline ccRCC focuses on systemic therapy doublets. Although effective, such combinations exhibit substantial toxicities and healthcare costs. An underutilized option is MRWS, which may facilitate a prolonged systemic therapy-free interval in select patients. Unfortunately, no reliable prognostic …

us (code pays fourni par la source)

Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial

Chad Tang, Alexander D. Sherry, Aaron Seo, Kieko Hara et autres

us (code pays fourni par la source)

Abstract CT132: Phase 2 trial of metastasis directed radiotherapy without systemic therapy (MRWS) for oligometastatic clear cell renal cell carcinoma (ccRCC) and investigation of circulating tumor DNA (ctDNA) as a personalized biomarker

Chad Tang, Alexander D. Sherry, Aaron Seo, Kieko Hara et autres

Abstract Background: Current treatment for frontline ccRCC focuses on systemic therapy doublets. Although effective, such combinations exhibit substantial toxicities and healthcare costs. An underutilized option is MRWS, which may facilitate a prolonged systemic therapy-free interval in select patients. Unfortunately, no reliable prognostic …

us (code pays fourni par la source)

Abstract TP343: Co-Expression Modules In The Periphreal Blood Transcriptome Following Subarachnoid Hemorrhage Associate With 90-Day Outcome

Bodie Knepp, Garreck Lenz, Heather Hull, Nerissa Ko et autres

Background: Subarachnoid Hemorrhage (SAH) accounts for 2-7% of strokes and has high mortality and morbidity. We sought to identify peripheral blood transcriptome changes in the acute SAH phase that associated with 90-day outcome, as measured by the modified Rankin Scale (mRS), to …

us, ca (code pays fourni par la source)

Abstract WP35: Neutrophil Extracellular Traps As a Biomarker for Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage

Hussein A. Zeineddine, Ari Dienel, Sithara Thomas, William Wroe et autres

Neutrophils are reported to be critical mediators of to poor outcome after subarachnoid hemorrhage (SAH). Following SAH, neutrophils cause vascular occlusion via neutrophil extracellular traps (NETs) and NETs have been identified as a therapeutic target to prevent delayed cerebral ischemia in mice …

us (code pays fourni par la source)

MA21.03 Preoperative Assessment of N2 Mediastinal Lymph Nodes in Non-small Cell Lung Cancer Using Ga-68 FAPI PET/CT: A Prospective Pilot Study

K.J. Na, Y.-K. Kang, Jong Ho Park, Nakwon Kwak et autres

kr (code pays fourni par la source)

MP55-03 USING MAGNETIC RESONANCE IMAGING TO DEFINE FOCAL THERAPY TEMPLATES IN PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER

Alberto Pieretti, Hyunseon Kang, Haesun Choi, Miao Zhang et autres

You have accessJournal of UrologyCME1 May 2022MP55-03 USING MAGNETIC RESONANCE IMAGING TO DEFINE FOCAL THERAPY TEMPLATES IN PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER Alberto Pieretti, Hyunseon Kang, Haesun Choi, Miao Zhang, Brian Chapin, John Ward, Patricia Troncoso, and Justin Gregg Alberto PierettiAlberto Pieretti …

Repeatability and Reproducibility Assessment of the Apparent Diffusion Coefficient in the Prostate: A Trial of the ECOG‐ACRIN Research Group ( ACRIN 6701)

Michael A. Boss, Bradley S. Snyder, Eun‐Hee Kim, Dena Flamini et autres

Background Uncertainty regarding the reproducibility of the apparent diffusion coefficient (ADC) hampers the use of quantitative diffusion‐weighted imaging (DWI) in evaluation of the prostate with magnetic resonance imaging MRI. The quantitative imaging biomarkers alliance (QIBA) profile for quantitative DWI claims a within‐subject …

us, de (code pays fourni par la source)

Gastrointestinal stromal tumours

Haesun Choi

Abstract Gastrointestinal stromal tumour (GIST) is rare, but the most common tumour of non-epithelial origin in the GI tract. It was often misdiagnosed as leiomyomas and leiomyosarcomas, with a dismal prognosis until KIT receptor protein was identified in the tumour cells. GISTs …

Impact of MRI/US fusion‐guided prostate biopsy on biopsy‐naïve patients: A single urologist’s experience

Muammer Altok, Cihan Demirel, Hyunseon C. Kang, Haesun Choi et autres

Objectives: To report our experience with imaging-guided targeted prostate biopsy (IGTpBx) for patients undergoing initial prostate biopsy in a clinical setting. Materials and methods: From July 2014 to February 2020, 305 men who had IGTpBx performed as their first prostate biopsy were …

us (code pays fourni par la source)